MDGL
Madrigal Pharmaceuticals, Inc.
$516.74
-0.45%
2026-08-21
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Key Fundamentals
Forward P/E
52.73
EPS (TTM)
$-14.01
ROE
-53.3%
Revenue Growth (YoY)
71.2%
Profit Margin
-25.3%
Debt/Equity
66.40
Price/Book
22.38
Beta
-1.00
Market Cap
$11.73B
Avg Volume (10D)
340K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$569.44
60D Low
$445.20
Avg Volume
362K
Latest Close
$516.74
Get breakout alerts for MDGL
Sign up for Breakout Scanner to receive daily notifications when MDGL triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Madrigal Pharmaceuticals, Inc. (MDGL) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors MDGL daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. MDGL operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.